乙酰唑胺
多导睡眠图
医学
高海拔对人类的影响
随机对照试验
安慰剂
呼吸暂停
脉搏血氧仪
缺氧(环境)
麻醉
内科学
周期性呼吸
氧气
病理
有机化学
化学
替代医学
解剖
作者
Laura C. Graf,Michael Furian,Konstantinos Bitos,Maamed Mademilov,Ainura Abdraeva,Jana C. Buenzli,Simone Buenzli,Shaira Aidaralieva,Ulan Sheraliev,Laura Mayer,Simon Schneider,Talant Sooronbaev,Silvia Ulrich,Konrad E. Bloch
出处
期刊:Sleep
[Oxford University Press]
日期:2022-11-10
卷期号:46 (4)
被引量:4
标识
DOI:10.1093/sleep/zsac269
摘要
To assess altitude-induced sleep and nocturnal breathing disturbances in healthy lowlanders 40 y of age or older and the effects of preventive acetazolamide treatment.Clinical examinations and polysomnography were performed at 760 m and in the first night after ascent to 3100 m in a subsample of participants of a larger trial evaluating altitude illness. Participants were randomized 1:1 to treatment with acetazolamide (375 mg/day) or placebo, starting 24 h before and while staying at 3100 m. The main outcomes were indices of sleep structure, oxygenation, and apnea/hypopnea index (AHI).Per protocol analysis included 86 participants (mean ± SE 53 ± 7 y old, 66% female). In 43 individuals randomized to placebo, mean nocturnal pulse oximetry (SpO2) was 94.0 ± 0.4% at 760 m and 86.7 ± 0.4% at 3100 m, with mean change (95%CI) -7.3% (-8.0 to -6.5); oxygen desaturation index (ODI) was 5.0 ± 2.3 at 760 m and 29.2 ± 2.3 at 3100 m, change 24.2/h (18.8 to 24.5); AHI was 11.3 ± 2.4/h at 760 m and 23.5 ± 2.4/h at 3100 m, change 12.2/h (7.3 to 17.0). In 43 individuals randomized to acetazolamide, altitude-induced changes were mitigated. Mean differences (Δ, 95%CI) in altitude-induced changes were: ΔSpO2 2.3% (1.3 to 3.4), ΔODI -15.0/h (-22.6 to -7.4), ΔAHI -11.4/h (-18.3 to -4.6). Total sleep time, sleep efficiency, and N3-sleep fraction decreased with an ascent to 3100 m under placebo by 40 min (17 to 60), 5% (2 to 8), and 6% (2 to 11), respectively. Acetazolamide did not significantly change these outcomes.During a night at 3100 m, healthy lowlanders aged 40 y or older revealed hypoxemia, sleep apnea, and disturbed sleep. Preventive acetazolamide treatment improved oxygenation and nocturnal breathing but had no effect on sleep duration and structure.The trial is registered at Clinical Trials, https://clinicaltrials.gov, NCT03561675.
科研通智能强力驱动
Strongly Powered by AbleSci AI